Ämnen: Haelso-sjukvaard

INTERIM ANALYSIS OF PHASE III STUDY SHOWS TAXOTERE®-BASED REGIMENS WITH HERCEPTIN® SIGNIFICANTLY IMPROVED DISEASE FREE SURVIVAL IN WOMEN WITH EARLY-STAGE HER2-POSITIVE BREAST CANCER

8 December 2005 16:53

Results from the BCIRG 006 study also show that a novel non-anthracycline-based regimen (“TCH”) with TAXOTERE® (docetaxel), the platinum salt carboplatin and HERCEPTIN® (trastuzumab) reduces the risk of recurrence without increasing cardiotoxicity in patients with early stage HER2-positive breast cancer Paris and San Antonio – December 8th, 2005 – The Breast Cancer International Research Group

FDA GRANTS PRIORITY REVIEW TO TAXOTERE FOR THE SUPPLEMENTAL NEW DRUG APPLICATION FOR ADVANCED GASTRIC CANCER

2 December 2005 13:29

Paris – December 2, 2005 – Sanofi-aventis announced today that the U.S Food and Drug Administration (FDA) has granted a six-month priority review for the supplemental new drug application (s-NDA) for Taxotere (docetaxel) Injection Concentrate, in combination with a current standard treatment (cisplatin and 5-fluorouracil) for advanced gastric cancer. The supplemental application is based on d

NEW ENGLAND JOURNAL OF MEDICINE PUBLICERAR RIO-LIPIDS-STUDIEN

17 November 2005 15:53

Studie visar att rimonabant signifikant reducerar kardiovaskulära och metabola riskfaktorer hos överviktiga och feta patienter Paris, Frankrike, 16 november 2005 – Sanofi-aventis tillkännagav att resultaten från RIO-Lipidsstudien publicerades i dag i The New England Journal of Medicine. I studien undersöktes effekten av rimonabant hos patienter med övervikt och fetma samt avvikande blodfetter (

INTERNATIONELL DIABETESUNDERSÖKNING BELYSER ATT PERSONER MED DIABETES OCH VÅRDGIVARE HAR OLIKA UPPFATTNINGAR OM SJUKDOMEN OCH HUR DEN SKA BEHANDLAS

14 November 2005 13:32

En stor undersökning som publiceras på World Diabetes Day 14 november 2005 visar att diabetiker i större utsträckning vill medverka vid beslut som rör behandlingen av sjukdomen. Paris, 14 november 2005 – Resultaten av en undersökning som publiceras idag på World Diabetes Day visar att nästan 80% av allmänheten personligen känner någon som har diabetes. För närvarande finns fler än 194 miljon

SANOFI PASTEUR SIGNS CONTRACT WITH FRENCH GOVERNMENT TO PRODUCE PANDEMIC INFLUENZA VACCINE

10 November 2005 10:19

Alain BERNAL Vice-President Corporate Communications Tel: + 33-(0)4-37-37-78-97 Fax: +33-(0)4-37-37-77 89 Len LAVENDA U.S. Media Relations Tel: +1-570-839-4446 Len.Lavenda@sanofipasteur.com ~ Influenza Vaccine Leader sanofi Pasteur Contributes to French Pandemic Preparedness ~ Lyon, France – November 10, 2005 – Following discussions which started a few months ago, sanofi pasteur,

APPOINTMENT OF JEAN-YVES WESSELY HEAD OF SANOFI-AVENTIS WINTHROP

25 Oktober 2005 15:35

Paris – October 24, 2005- Effective october 2oo5, Jean-Yves Wessely is appointed Senior Vice President in charge of Winthrop, worldwide Generics Activities of sanofi-aventis, based in Paris. Jean-Yves Wessely, MD, brings with him a wealth of more than 25 years of experience in the pharmaceutical industry, as well as an intimate knowledge of Winthrop's key markets, having held several regional a

EXUBERA® INHALED INSULIN IMPROVES BLOOD SUGAR LEVELS IN ADULTS WITH TYPE 2 DIABETES BETTER THAN DIABETES PILLS ALONE 1

20 Oktober 2005 15:55

Paris, 2005-10-20: Adults with type 2 diabetes taking Exubera (insulin human) alone or in combination with diabetes pills achieved significantly greater reductions in blood sugar levels compared to patients taking pills alone, according to a new study published in the October issue of Annals of Internal Medicine. Läs mer i bifogad fil. See attached document.

EXUBERA® RECEIVES POSITIVE OPINION FROM CHMP FOR THE TREATMENT OF TYPE 1 + TYPE 2 DIABETES

14 Oktober 2005 14:03

Paris October 14, 2005 – Sanofi-aventis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) issued a positive opinion recommending approval of EXUBERA (insulin human), an inhalable form of insulin, for the treatment of type 1 and type 2 diabetes. The proposed therapeutic indication for Exubera is for the treatment of adult pati

TELITHROMYCIN AGAINST STREPTOCOCCUS PNEUMONIAE SHOWN SUPERIOR

21 September 2005 09:33

MICROBIOLOGICAL ACTIVITY OF TELITHROMYCIN AGAINST STREPTOCOCCUS PNEUMONIAE SHOWN SUPERIOR TO OTHER STANDARD FIRST LINE ANTIBIOTICS OVER 4-YEAR PERIOD New data demonstrates that in vitro activity of Ketek (telithromycin) remained consistently high on S. pneumoniae with at least 99.8% of the isolates being susceptible Paris, 20 September 2005 – Data presented today at the 15th Annual Internati

TAXOTERE®-BASED CHEMOTHERAPY REGIMENS COMBINED WITH HERCEPTIN® SIGNIFICANTLY IMPROVED DISEASE FREE SURVIVAL IN EARLY-STAGE HER2-POSITIVE BREAST CANCER

15 September 2005 13:41

INTERIM ANALYSIS OF PHASE III STUDY SHOWS TAXOTERE® (docetaxel)- BASED CHEMOTHERAPY REGIMENS COMBINED WITH HERCEPTIN® (trastuzumab) SIGNIFICANTLY IMPROVED DISEASE FREE SURVIVAL IN EARLY-STAGE HER2-POSITIVE BREAST CANCER Interim analysis of more than 3,000 patients in BCIRG006 study also shows TAXOTERE® non-anthracycline-based chemotherapy combined with HERCEPTIN® improved disease-free surviv

DATA AT EASD SUGGESTS BETTER GLYCAEMIC CONTROL POSSIBLE USING INSULIN GLARGINE OR INSULIN GLULISINE IN TYPE 2 DIABETES

15 September 2005 08:55

Studies show impact of enforced titration of Lantus® (insulin glargine) on reducing HbA1C levels, and Apidra® (insulin glulisine) on postprandial glucose control in patients with type 2 diabetes Athens September 14th, 2005: Data presented at the 41st Annual Meeting of the European Association for the Study of Diabetes (EASD), Athens show that a strictly enforced titration schedule with intensiv

Strong growth in 2005 first half adjusted EPS : up 26.1% at €2.22

31 Augusti 2005 09:44

Increase in full year adjusted EPS guidance Positive phase IIb/III results for 6 products

Ny studie visar stora skillnader i överlevnad inom samma klass bröstcancermedicin

18 Augusti 2005 12:10

I dagens nummer av Journal of Clinical Oncology: Ny studie visar stora skillnader i överlevnad inom samma klass bröstcancermedicin I dagens nummer av den internationella tidskriften Journal of Clinical Oncology har resultaten av den första jämförande studie av olika cellgifter publicerats. I studien jämförs två av de vanligaste cellgifterna vid behandling av avancerad bröstcancer, docetaxel

RESOLUTION OF UK PLAVIX® LITIGATION

8 Augusti 2005 13:55

Today sanofi-aventis announced that Aircoat has withdrawn the revocation action by which it had sought to invalidate the sanofi-aventis patent in the UK claiming clopidogrel bisulfate. Aircoat’s revocation action was originally announced in January 2005. About sanofi-aventis Sanofi-aventis is the world’s 3rd largest pharmaceutical company, ranking number 1 in Europe. Backed by a world-class R&

SANOFI-AVENTIS SELLS ITS INTERESTS IN WACKER-CHEMIE

8 Augusti 2005 08:55

- Hoechst AG, a subsidiary of sanofi-aventis, and the Wacker family agreed on the restructuring of the ownership of Wacker-Chemie GmbH.

Allegra-D® 24 hour (fexofenadine HCl 180 mg/pseudoephedrine HCl 240 mg) Extended Release Tablets now available in the United-States for seasonal allergy sufferers

28 Juli 2005 09:57

Allegra-D® 24 hour (fexofenadine HCl 180 mg/pseudoephedrine HCl 240 mg) Extended Release Tablets now available in the United-States for seasonal allergy sufferers Läs mer http://en.sanofi-aventis.com/index.asp

Sanofi pasteur Begins Shipping ADACEL™ Vaccine in the U.S. for Combined Protection against Tetanus, Diphtheria, and Pertussis

25 Juli 2005 16:14

Läs mer på http://en.sanofi-aventis.com/press/p_press.asp

Strong net sales growth in the first half of 2005

19 Juli 2005 09:41

Strong net sales growth in the first half of 2005: 11.0% on a comparable basis. Further increase in market share in the second quarter.

TRANSFER OF COMMERCIAL RIGHTS OF PLAVIX® IN JAPAN TO SANOFI-AVENTIS

5 Juli 2005 10:53

- Sanofi-aventis and Daiichi Pharmaceutical Co., Ltd. announced today the transfer of all commercial rights for Plavix® (clopidogrel) in Japan from Daiichi and a jointly held partnership to sanofi-aventis Japan. The transfer will be implemented in conformity with local regulatory requirements. Given their long-standing partnership, both parties agreed to collaborate in the future in the areas

PANEL OF EXPERTS AGREE THAT BONE MINERAL DENSITY IS NO LONGER ENOUGH

5 Juli 2005 10:43

Understanding the Factors Which Contribute to Bone Strength Geneva, Switzerland, 28 June, 2005— The Alliance for Better Bone Health announced today that according to evidence presented by an international panel of osteoporosis experts, Bone Mineral Density (BMD) testing does not accurately reflect all factors important to bone strength. The panel’s findings, presented at the Second Joint Meetin